(Total Views: 356)
Posted On: 09/05/2018 6:55:35 PM
Post# of 153964
NetworkNewsBreaks – CytoDyn Inc. (CYDY) to Develop PRO 140 as Therapy for Triple-Negative Breast Cancer
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning detailed its plan to develop PRO 140 (leronlimab) as a therapy for metastatic triple-negative breast cancer. Per the update, previously announced findings from preclinical studies showed the ability of PRO 140 to block human breast cancer cellular invasion in a surrogate assay for metastatic breast cancer. “We plan to aggressively pursue the development of PRO 140 as a therapy for women with metastatic triple-negative breast cancer, which is in keeping with our strategy to evaluate PRO 140 in certain cancers and immunological indications where CCR5 antagonism has shown initial promise,” Nader Pourhassan, Ph.D., president and CEO of CytoDyn, stated in the news release. “In addition, we are continuing to move forward with plans to assess PRO 140 in metastatic colon cancer… We are pleased with our recent progress toward filing a Biologics License Application (BLA) for PRO 140 as a combination therapy for HIV and are confident that two thirds of our BLA submission will be completed by the end of 2018 and the last section, Chemistry, Manufacturing and Controls (CMC), by first quarter of 2019.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning detailed its plan to develop PRO 140 (leronlimab) as a therapy for metastatic triple-negative breast cancer. Per the update, previously announced findings from preclinical studies showed the ability of PRO 140 to block human breast cancer cellular invasion in a surrogate assay for metastatic breast cancer. “We plan to aggressively pursue the development of PRO 140 as a therapy for women with metastatic triple-negative breast cancer, which is in keeping with our strategy to evaluate PRO 140 in certain cancers and immunological indications where CCR5 antagonism has shown initial promise,” Nader Pourhassan, Ph.D., president and CEO of CytoDyn, stated in the news release. “In addition, we are continuing to move forward with plans to assess PRO 140 in metastatic colon cancer… We are pleased with our recent progress toward filing a Biologics License Application (BLA) for PRO 140 as a combination therapy for HIV and are confident that two thirds of our BLA submission will be completed by the end of 2018 and the last section, Chemistry, Manufacturing and Controls (CMC), by first quarter of 2019.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
